Business Context and Reporting Period
The provided filing is a Form 10-Q for the quarter and six months ended June 30, 2012, filed August 14, 2012. The filing identifies the registrant as Bond Laboratories, Inc., not FitLife Brands, Inc.; investors should verify the company identity and filing association.
Bond Laboratories, through NDS Nutrition Products, Inc., develops, manufactures and markets nutritional supplements, primarily through GNC franchise locations in the United States. The company marketed more than 50 products through over 900 GNC franchise locations and shipped its first international orders during the quarter. The interim financial statements are unaudited and prepared under GAAP interim-reporting requirements.
Financial Highlights
| Metric | Three months ended June 30, 2012 | Three months ended June 30, 2011 | Six months ended June 30, 2012 | Six months ended June 30, 2011 |
|---|---|---|---|---|
| Revenue | $5.18 million | $3.17 million | $10.13 million | $6.16 million |
| Gross profit | $1.97 million | $1.13 million | $3.72 million | $2.19 million |
| Operating income | $777,290 | $404,789 | $1.50 million | $511,363 |
| Net income | $772,950 | $394,600 | $1.49 million | $491,717 |
| Basic EPS | $0.01 | $0.01 | $0.02 | $0.01 |
- Quarterly revenue increased approximately 63%; six-month revenue increased approximately 65%.
- Quarterly gross margin was approximately 38.2%, compared with 35.6%; six-month gross margin was approximately 36.7%, compared with 35.6%.
- Quarterly operating margin was approximately 15.0%, compared with 12.8%; six-month operating margin was approximately 14.8%, compared with 8.3%.
- Quarterly net margin was approximately 14.9%, compared with 12.5%; six-month net margin was approximately 14.7%, compared with 8.0%.
- Six-month cash provided by operating activities was $250,366, compared with cash used in operations of $86,712 in the prior-year period. Investing cash flow was zero, and financing cash flow was zero.
- Cash increased to $605,295 at June 30, 2012, from $354,929 at December 31, 2011. Accounts receivable increased to $2.10 million from $1.04 million, and inventory increased to $2.84 million from $1.88 million.
- Total assets were $7.00 million, compared with $4.82 million at year-end. Current liabilities were $2.25 million, compared with $1.62 million, producing a current ratio of approximately 2.5 times versus 2.0 times.
- Debt consisted primarily of a $437,089 revolving line of credit, classified as current, bearing interest at 3.5% plus one-month LIBOR and maturing May 15, 2013. The line is secured by specified receivables and inventory.
- Accounts payable increased to $1.38 million from $767,171. A $250,000 litigation reserve remained recorded at June 30, 2012.
Material Changes Versus the Prior Comparable Period
- Management attributed revenue growth to strong sales of recently introduced products and higher average sales per retail location. International sales began but were not material in the quarter.
- General and administrative expense increased to $597,831 for the quarter from $257,137, primarily because of legal costs related to the Schick litigation. Six-month general and administrative expense increased to $1.12 million from $813,621.
- Selling and marketing expense increased to $539,101 for the quarter from $398,073, reflecting expanded marketing activity. Six-month expense increased to $982,526 from $733,092.
- Approximately 30% of quarterly revenue was attributable to products containing DMAA. The company introduced reformulated products excluding DMAA, creating uncertainty regarding replacement-product sales.
- Shares outstanding increased to 74,490,670 at June 30, 2012 from 74,171,996 at December 31, 2011. The diluted share count was substantially higher than the basic share count because of potential shares from preferred stock, warrants and options.
- The company issued 191,667 common shares for services and granted 700,000 stock options to employees and directors during the quarter.
Guidance, Outlook, Risks, Contingencies and Unusual Items
- Management expected existing cash resources and anticipated operating cash flow to support liquidity through at least December 31, 2012, and believed operating cash flow could fund working capital needs beyond that date. This is management’s expectation, not formal quantitative guidance.
- Management expected continued expansion of store coverage, approved products and international distribution to support future growth, but provided no specific revenue or earnings targets.
- Effective August 3, 2012, the company settled all pending Schick-related litigation without admitting wrongdoing. Payments total $360,000, including $180,000 payable over twelve months, and the company or its designee must purchase 600,000 shares held by Schick. The litigation reserve was $250,000, so the filing text does not clearly state the final accounting impact of the settlement.
- A separate CycloBolan product-liability action sought initial damages of $500,000. The insurer assumed the defense at no cost to the company, and management characterized the risk as minimal, although the filing states that the likelihood and amount of any loss could not yet be evaluated.
- DMAA-related regulatory and product-liability exposure is a significant risk. The FDA questioned the safety and dietary-ingredient status of DMAA, and the company warned that weaker sales of reformulated products could materially affect revenue.
- The company maintained a full valuation allowance against remaining deferred tax assets and stated that net operating losses may be limited under Internal Revenue Code Section 382. It restored $420,000 of the valuation allowance during the quarter based on expected utilization, while also stating that a full valuation allowance remained at June 30, 2012.
- Management reported effective disclosure controls and internal control over financial reporting as of June 30, 2012. The filing was not subject to an external auditor attestation of internal controls.
Key Facts for Investors to Verify
- Confirm that this Bond Laboratories filing is the intended source for the requested FitLife Brands 2012 second-quarter summary.
- Assess customer concentration and dependence on GNC franchise locations, as well as the sustainability of recent product-driven growth.
- Reconcile the Schick settlement’s $360,000 obligation with the existing $250,000 litigation reserve and determine the required cash and equity accounting.
- Monitor DMAA regulatory developments, product reformulation performance and potential product-liability claims.
- Evaluate working-capital requirements as accounts receivable and inventory grew substantially faster than year-end balances.
- Review the May 2013 maturity, collateral terms and borrowing availability under the $437,089 revolving line of credit.
- Consider dilution from 15.0 million outstanding warrants, 1.2 million options and 5.0 million shares issuable upon conversion of Series C preferred stock.
- Verify the tax treatment and realizability of net operating loss carryforwards, including potential Section 382 limitations.